<DOC>
	<DOCNO>NCT00365352</DOCNO>
	<brief_summary>The primary objective trial ass efficacy XP13512 take daily compare placebo treatment patient suffer Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>XP13512 v . Placebo Patients With Restless Legs Syndrome .</brief_title>
	<detailed_description>This 12-week , multicenter , randomize , double-blind , placebo-controlled , parallel-group study ass efficacy safety XP13512 subject Restless Legs Syndrome ( RLS ) . Eligible subject randomize receive 1 3 daily oral dos XP13512 1200 mg , XP13512 600 mg , placebo . The primary study objective compare efficacy XP13512 1200 mg take daily 12 week versus placebo . The secondary study objective assess efficacy XP13512 600 mg take daily reatment RLS ass onset treatment benefit improvement sleep , pain , mood , quality life , safety tolerability XP13512 1200 mg 600 mg .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients primary RLS , base International RLS Study Diagnostic Criteria . A sleep disorder ( e.g. , sleep apnea ) may significantly affect assessment RLS ; Neurologic disease movement disorder ( e.g. , diabetic neuropathy , Parkinson 's Disease , Multiple Sclerosis , dyskinesia , dystonias ) ; Abnormal laboratory result , electrocardiogram ( ECG ) physical finding ; Pregnant lactate woman ; Women childbearing potential practicing acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>